On January 20, upstream reporters learned from the Chongqing Municipal Food and Drug Administration that the Indonesian Food and Drug Administration (BPOM) recently held a press conference to announce that the Institute of Microbiology of the Chinese Academy of Sciences and Anhui Zhifei Longkema Biopharmaceutical Co., Ltd., a subsidiary of Chongqing Zhifei Biological Products Co., Ltd., jointly developed a recombinant novel coronavirus vaccine (CHO cell), (Zifivax) was approved as a sequential (heterologous) booster for the new crown inactivated vaccine.
It is reported that the recombinant novel coronavirus vaccine (CHO cell) as a "genetically engineered recombinant subunit vaccine", through the genetic engineering of the expression of purified pathogen antigen proteins in engineered cells prepared, has completely independent intellectual property rights. The vaccine was registered and marketed in Uzbekistan on March 1, 2021, becoming the first recombinant subunit COVID-19 vaccine to be registered and marketed in the world, approved for emergency use in China on March 10, 2021, and urgent use in Indonesia on October 7, 2021.
According to the information on the official website of Chongqing Zhifei Biology, the results of the international multi-center Phase III clinical trial show that the protective efficacy of the vaccine against any severity of COVID-19 is 81.43%, meeting the WHO requirements of the new crown vaccine effectiveness standard. The preliminary genotyping results showed that the protective efficacy of the vaccine against the Alpha variant was 92.68% and the protective efficacy against the Delta strain was 81.38%.
At present, more than 100 new crown vaccines have entered clinical trials around the world, including inactivated vaccines, recombinant protein subunit vaccines, viral vector vaccines, nucleic acid vaccines (mRNA vaccines) and other vaccine varieties of R&D production processes.
Wang Ming, chief expert of the Guangzhou Preventive Medicine Association, said in an interview that heterologous vaccines are complementary and can play the role of 1+1>2. Because sequential vaccination using different technical pathways is expected to increase the intensity, breadth and persistence of the immune response through complementarity between different mechanisms, resulting in more comprehensive and powerful protection.
Upstream journalist Chen Yu text/photo
![The world's largest! The first sequential clinical study of the New Coronavirus vaccine of the Austrian strain was launched[fig]](data:image/gif;base64,R0lGODlhAQABAIAAAP///wAAACwAAAAAAQABAAACAkQBADs=)